Takeda Drug Gets Priority FDA Review
Takeda and Protagonist Therapeutics announced the FDA has accepted their New Drug Application for Rusfertide and granted it priority review. The drug is a first-in-class therapy for the blood disorder polycythemia vera, and the designation could speed its path to market.
A priority review designation from the FDA sets a goal for a six-month review process, a significant reduction from the standard ten months. This accelerated timeline is reserved for drugs that may offer substantial improvements in the treatment of serious conditions. Rusfertide operates as a hepcidin mimetic, a new approach to treating polycythemia vera. By mimicking the natural hormone hepcidin, the drug regulates iron availability in the body, which in turn controls the overproduction of red blood cells that characterizes the disease. The New Drug Application is supported by the Phase 3 VERIFY study, which met all its primary and secondary endpoints. In the trial, 77% of patients treated with Rusfertide achieved the desired clinical response, compared to just 33% of those who received a placebo. The drug also significantly reduced the need for phlebotomies, a common procedure for patients. The global market for polycythemia vera treatments was valued at approximately $1.9 billion in 2024. A key existing treatment is JAKAFI (ruxolitinib), which generated around $965 million in U.S. revenue in 2024. With its novel mechanism, Rusfertide is positioned to challenge the current standard of care. This submission triggers the terms of a worldwide collaboration agreement signed between Takeda and Protagonist in early 2024. Takeda made an upfront payment of $300 million for the rights to co-develop and co-commercialize the drug. Under the agreement, Protagonist handles development through the U.S. regulatory filing. Post-approval, Takeda will lead global commercialization, with Protagonist having an option to co-promote in the U.S. for a 50/50 profit split. Protagonist is also eligible for further milestone payments and royalties on sales outside the United States.
